Known as VS-6063, or defactinib, this cancer-stem-cell inhibitor manufactured by Verastem Inc. was given orphan drug designation by the FDA for treatment of mesothelioma.
Known as VS-6063, or defactinib, this cancer-stem-cell inhibitor manufactured by Verastem Inc. was given orphan drug designation by the FDA for treatment of mesothelioma.